Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is well-positioned for growth with its innovative technology, expansion plans, and focus on reducing costs and debt while increasing productivity. The company's partnerships and strong presence in the healthcare industry provide a solid foundation for future success. With a promising market opportunity and a target price of $62 per share, MDLN is a strong investment choice for long-term growth.

Bears say

Medline is in a strong position in the medical-surgical industry with its extensive product offerings, scale, and distribution network. However, risks such as increased competition, disruptions in the industry, and potential product malfunctions or delays could hinder its growth potential. The company's ongoing investments in technology and automation will drive operating leverage and margin expansion, but its current level of debt and potential for acquisitions may pose financial risks. Overall, while Medline has the potential for future growth, there are concerns that could negatively impact its performance and limit potential shareholder value.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Jun 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.